Blog Post

Blog Post

FDA Approves ITF Pharma’s Tiglutik via PEG Tube for the Treatment of ALS

By Jeanene Swanson | December 20, 2019
Blog Post

Amylyx Pharmaceuticals Announces Positive Results from Phase 2 Study of AMX0035 for Treatment of ALS

By Jeanene Swanson | December 19, 2019
Blog Post

Santhera Pharmaceuticals Announces Publication of Positive Long-Term Results from Retrospective Study of Idebenone in DMD

By Jeanene Swanson | December 18, 2019
MDA logo
Blog Post

Solid Biosciences Releases Letter to DMD Community Announcing Update on IGNITE DMD Trial, Resolution of Serious Adverse Event

By MDA Staff | December 18, 2019
MDA logo
Blog Post

Wave Life Sciences Releases Letter to DMD Community Announcing Discontinuation of Clinical Trials Program for Therapies Amenable to Skipping Exons 51 and 53

By MDA Staff | December 16, 2019
Illustration of DNA
Blog Post

FDA Approves Sarepta Therapeutics’ Vyondys 53 for Treatment of DMD Amenable to Exon 53 Skipping

By Jeanene Swanson | December 13, 2019
Blog Post

New MDA Educational Programs for Clinicians Offer a Detailed View on Selected Topics in Neuromuscular Disease

By MDA Staff | December 13, 2019
Blog Post

FDA Approves Aquestive Therapeutics’ Exservan for the Treatment of ALS

By Jeanene Swanson | December 6, 2019
Blog Post

Kadimastem Announces Positive Interim Results from Phase 1/2a Study of AstroRx in ALS

By Jeanene Swanson | December 5, 2019
Illustration of DNA
Blog Post

FDA Accepts Roche Genentech’s NDA for Risdiplam for the Treatment of SMA

By Jeanene Swanson | December 3, 2019